“…In light of the poor prognosis associated with advanced HCC, there is a need to prioritize patient centered outcomes such as quality of life (QoL). Particularly, there is a strong evidence base regarding the prognostic value of health-related quality of life (HRQoL), the patients’ individual perception about their life in regards to goals, standards and concerns, and expectations with respect to their diagnosis, in the oncological setting [46,47,48,49,50,51,52]. In spite of this knowledge, there is a paucity of published data evaluating the impact of FDA-approved therapeutics on patient-centered outcomes such as HRQoL for those patients included in advanced HCC clinical trials.…”